These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31077329)

  • 1. Addition of Platinum Derivatives to Fluoropyrimidine-Based Neoadjuvant Chemoradiotherapy for Stage II/III Rectal Cancer: Systematic Review and Meta-Analysis.
    Hüttner FJ; Probst P; Kalkum E; Hackbusch M; Jensen K; Ulrich A; Debus J; Jäger D; Diener MK
    J Natl Cancer Inst; 2019 Sep; 111(9):887-902. PubMed ID: 31077329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064).
    Hüttner FJ; Probst P; Kalkum E; Hackbusch M; Jensen K; Ulrich A; Büchler MW; Diener MK
    Syst Rev; 2018 Jan; 7(1):11. PubMed ID: 29357929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
    Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
    Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis.
    Liu S; Jiang T; Xiao L; Yang S; Liu Q; Gao Y; Chen G; Xiao W
    Oncologist; 2021 Sep; 26(9):e1555-e1566. PubMed ID: 33987952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.
    Fu XL; Fang Z; Shu LH; Tao GQ; Wang JQ; Rui ZL; Zhang YJ; Tian ZQ
    Oncotarget; 2017 May; 8(21):34340-34351. PubMed ID: 28423720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis.
    Song JH; Lee JH; Kim SH; Um JW;
    Int J Colorectal Dis; 2022 Mar; 37(3):649-656. PubMed ID: 35050402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
    Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical, oncological, and functional outcomes of local and radical resection after neoadjuvant chemotherapy or chemoradiotherapy for early- and mid-stage rectal cancer: a systematic review and meta-analysis.
    Tan S; Ou Y; Huang S; Gao Q
    Int J Colorectal Dis; 2023 May; 38(1):132. PubMed ID: 37193915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
    Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological Complete Response Following Different Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.
    Hoendervangers S; Burbach JPM; Lacle MM; Koopman M; van Grevenstein WMU; Intven MPW; Verkooijen HM
    Ann Surg Oncol; 2020 Oct; 27(11):4319-4336. PubMed ID: 32524461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy (CAPOX) alone for low- and intermediate-risk stage II/III rectal cancer: Long-term follow-up of a prospective single-arm study.
    Shen Y; Wu Q; Meng W; Wei M; Deng X; Wang Z
    Eur J Surg Oncol; 2023 Dec; 49(12):107115. PubMed ID: 37839296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis.
    Ceelen W; Fierens K; Van Nieuwenhove Y; Pattyn P
    Int J Cancer; 2009 Jun; 124(12):2966-72. PubMed ID: 19253365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer.
    Kim JM; Park JW; Lee JH; Park YH; Park SJ; Cheon JH; Kim WH; Kim TI
    Dis Colon Rectum; 2020 Jun; 63(6):758-768. PubMed ID: 32384406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Total Neoadjuvant Treatment Beneficial for Locally Advanced Rectal Cancer? A Meta-Analysis of Randomized Controlled Trials.
    Wu HQ; Li J; Miao JD; Li JW
    Oncology; 2024; 102(5):399-413. PubMed ID: 37926087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lateral lymph node dissection reduces local recurrence of locally advanced lower rectal cancer in the absence of preoperative neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
    Gao X; Wang C; Yu Y; Singh D; Yang L; Zhou Z
    World J Surg Oncol; 2020 Nov; 18(1):304. PubMed ID: 33228677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.